Comparative Efficacy of Immunosuppressive Therapies in the Treatment of Diffuse Cutaneous Systemic Sclerosis
Objectives The RESOLVE‐1 trial of lenabasum in diffuse cutaneous systemic sclerosis (dcSSc) allowed background immunosuppressive therapy (IST) at the discretion of individual investigators, and no significant differences were observed between treatment arms. This provides a powerful opportunity to c...
Saved in:
| Main Authors: | Barbara White, Daniel E. Furst, Tracy M. Frech, Masataka Kuwana, Laura Hummers, Wendy Stevens, Suzanne Kafaja, Eun Bong Lee, Oliver Distler, Dinesh Khanna, Christopher P. Denton, Robert Spiera, for the RESOLVE‐1 investigators |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-03-01
|
| Series: | ACR Open Rheumatology |
| Online Access: | https://doi.org/10.1002/acr2.70004 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Autoantibodies, cutaneous subset and immunosuppressants contribute to the cancer risk in systemic sclerosis
by: Maria De Santis, et al.
Published: (2024-09-01) -
Cutaneous Coinfection of Cytomegalovirus and Mycobacterium chelonae Accelerated by Immunosuppression
by: Yutaka Tsutsumi, et al.
Published: (2021-01-01) -
Recent advances in clinical and pathological significance of autoantibodies
by: Masataka Kuwana
Published: (2025-04-01) -
Immunosuppression and Outcomes in Patients with Cutaneous Squamous Cell Carcinoma of the Head and Neck
by: Doriana Iancu, et al.
Published: (2025-01-01) -
Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases
by: Elizabeth R Volkmann, et al.
Published: (2024-12-01)